Published in Mental Health Business Week, January 27th, 2007
AstraZeneca's determination to continue development triggers a $20 million milestone payment to Targacept under the parties' collaboration agreement. The announcement follows the completion by AstraZeneca of previously announced studies of AZD3480 (TC-1734).
Alzheimer disease is an area of medical need in the developed and developing world. Schizophrenia is a chronic, severe and disabling form of psychosis that, in addition to symptoms such as delusions and hallucinations, is often...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.